Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co. (NYSE:LLY), disclosed the sale of shares worth approximately $183.6 million, according to recent filings. The transactions, which ...

Ratings has upgraded the issuer rating and senior unsecured notes ratings of global pharmaceutical company Eli Lilly and ...

The markets have succumbed to the headline pressure around inflation and tariffs, with all three of the major stock market indices trading in the red as of mid-morning. U.S. job growth slowed in ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

You might resent having to pay premiums, but when disaster or just a minor fender-bender happens, you'll be happy you have ...

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Wall Street drifted through a mixed day of trading as rising fashion and cigarette stocks worked against drops for Ford Motor ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.